Gavin Giovannoni

Citace

	Všechny	Od 2020
Citace	71804	32146
h-index	123	82
i10-index	605	406

7000

3500

1750

5250

2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025179 173 258 479 627 704 878 1044 1143 1567 2115 2373 3033 3180 3446 3449 4150 4357 4922 5656 6531 6470 6188 6035 1180

Veřejný přístup

Zobrazit všechny

183 článků

24 článků

dostupné

nedostupné

Vychází ze zplnomocnění pro financování

Spoluautoři

Ludwig KapposUniversity of Basel and Research Center of Clinical Neuroimmunology and Neuroscience Basel (RC2NB)E-mailová adresa ověřena na: uhbs.ch
Amit Bar-OrProfessor, University of PennsylvaniaE-mailová adresa ověřena na: pennmedicine.upenn.edu
Ruth DobsonCentre for Preventive Neurology, Wolfson Institute of Population Health, QMULE-mailová adresa ověřena na: qmul.ac.uk
Klaus SchmiererThe Blizard Institute, Queen Mary University of London, Medicine & Dentistry//Barts Health NHS TrustE-mailová adresa ověřena na: qmul.ac.uk
Xavier MontalbanE-mailová adresa ověřena na: cem-cat.org
Fred LublinIcahn School of Medicine at Mount SinaiE-mailová adresa ověřena na: mssm.edu
David BakerCannabis ExtraordinaireE-mailová adresa ověřena na: sflmusic.com
Jerry S Wolinsky, MDEmeritus Professor in Neurology, McGovern Medical School, UTHealth, The University of Texas HealthE-mailová adresa ověřena na: uth.tmc.edu
Robert J FoxMellen Center for Multiple Sclerosis, Cleveland ClinicE-mailová adresa ověřena na: ccf.org
michael HutchinsonUniversity College DublinE-mailová adresa ověřena na: ucd.ie
Stephen L. HauserUCSFE-mailová adresa ověřena na: ucsf.edu
Monica MartaBarts Health NHS Trust and Blizard Institute/ QMUL, LondonE-mailová adresa ověřena na: qmul.ac.uk
Christopher H HawkesHonorary Professor of Neurology, Queen Mary, University of LondonE-mailová adresa ověřena na: qmul.ac.uk
Jonathan BestwickSenior Lecturer in Medical Statistics, Queen Mary University of LondonE-mailová adresa ověřena na: qmul.ac.uk
Shibeshih Mitiku BelachewBiogenE-mailová adresa ověřena na: biogen.com
Axel PetzoldUCL, The National Hospital for Neurology and Neurosurgery & Moorfields Eye HospitalE-mailová adresa ověřena na: ucl.ac.uk
Alasdair ColesUniversity of CambridgeE-mailová adresa ověřena na: medschl.cam.ac.uk
Jeffrey A CohenCleveland ClinicE-mailová adresa ověřena na: ccf.org
Douglas Lorne Arnold, MD, FRCP(C)James McGill Professor: Department of Neurology and Neurosurgery, Faculty of Medicine, McGillE-mailová adresa ověřena na: mcgill.ca
Russell C DaleUniversity of SydneyE-mailová adresa ověřena na: health.nsw.gov.au

Sledovat

Gavin Giovannoni

Queen Mary University of London

E-mailová adresa ověřena na: giovannoni.net - Domovská stránka

neurology


Název Seřadit podle citací Seřadit podle roku Seřadit podle názvu	Citace Citace	Rok
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis CH Polman, PW O'Connor, E Havrdova, M Hutchinson, L Kappos, ... New England Journal of Medicine 354 (9), 899-910, 2006	4170	2006
Multiple sclerosis–a review R Dobson, G Giovannoni European journal of neurology 26 (1), 27-40, 2019	2328	2019
Ocrelizumab versus placebo in primary progressive multiple sclerosis X Montalban, SL Hauser, L Kappos, DL Arnold, A Bar-Or, G Comi, ... New england journal of medicine 376 (3), 209-220, 2017	2133	2017
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis R Gold, L Kappos, DL Arnold, A Bar-Or, G Giovannoni, K Selmaj, ... New England Journal of Medicine 367 (12), 1098-1107, 2012	2133	2012
Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis SL Hauser, A Bar-Or, G Comi, G Giovannoni, HP Hartung, B Hemmer, ... New England Journal of Medicine 376 (3), 221-234, 2017	2058	2017
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial JA Cohen, AJ Coles, DL Arnold, C Confavreux, EJ Fox, HP Hartung, ... The Lancet 380 (9856), 1819-1828, 2012	1327	2012
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis G Giovannoni, G Comi, S Cook, K Rammohan, P Rieckmann, ... New England Journal of Medicine 362 (5), 416-426, 2010	1224	2010
Meta‐analysis of early nonmotor features and risk factors for Parkinson disease AJ Noyce, JP Bestwick, L Silveira‐Moriyama, CH Hawkes, G Giovannoni, ... Annals of neurology 72 (6), 893-901, 2012	1136	2012
A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution SV Ramagopalan, A Heger, AJ Berlanga, NJ Maugeri, MR Lincoln, ... Genome research 20 (10), 1352-1360, 2010	1126	2010
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ... The Lancet 391 (10127), 1263-1273, 2018	1080	2018
Multiple sclerosis: risk factors, prodromes, and potential causal pathways SV Ramagopalan, R Dobson, UC Meier, G Giovannoni The Lancet Neurology 9 (7), 727-739, 2010	820	2010
A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking CE Teunissen, A Petzold, JL Bennett, FS Berven, L Brundin, M Comabella, ... Neurology 73 (22), 1914-1922, 2009	810	2009
Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement MS Freedman, EJ Thompson, F Deisenhammer, G Giovannoni, ... Archives of neurology 62 (6), 865-870, 2005	800	2005
The peripheral benzodiazepine binding site in the brain in multiple sclerosis: Quantitative in vivo imaging of microglia as a measure of disease activity RB Banati, J Newcombe, RN Gunn, A Cagnin, F Turkheimer, F Heppner, ... Brain 123 (11), 2321-2337, 2000	788	2000
Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies G Giovannoni, JD O'sullivan, K Turner, AJ Manson, AJL Lees Journal of Neurology, Neurosurgery & Psychiatry 68 (4), 423-428, 2000	768	2000
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases DB Clifford, A DeLuca, DM Simpson, G Arendt, G Giovannoni, A Nath The Lancet Neurology 9 (4), 438-446, 2010	754	2010
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing … E Havrdova, S Galetta, M Hutchinson, D Stefoski, D Bates, CH Polman, ... The Lancet Neurology 8 (3), 254-260, 2009	613	2009
Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis CH Lu, C Macdonald-Wallis, E Gray, N Pearce, A Petzold, N Norgren, ... Neurology 84 (22), 2247-2257, 2015	575	2015
The therapeutic potential of cannabis D Baker, G Pryce, G Giovannoni, AJ Thompson The Lancet Neurology 2 (5), 291-298, 2003	567	2003
Brain health: time matters in multiple sclerosis G Giovannoni, H Butzkueven, S Dhib-Jalbut, J Hobart, G Kobelt, G Pepper, ... Multiple sclerosis and related disorders 9, S5-S48, 2016	546	2016

Systém momentálně nemůže danou operaci provést. Zkuste to znovu později.

Články 1–20

Citace za rok

Duplicitní citace

Sloučené citace

Přidat spoluautorySpoluautoři

Sledovat

Citace

Spoluautoři